TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: reproductive health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self‐efficacy in contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Carrot liking and intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sweetcorn intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Injection pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean nasal congestion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak nasal inspiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak C-reactive protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average nodes removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average time for detecting each SLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of axillary node
Endpoint domain: Adverse events/effects
Primary endpoint: Change in eicosapentaenoic acid (EPA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in arachidonic acid (AA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: analgesic medication requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of post herpetic neuralgia
Endpoint domain: Adverse events/effects
Primary endpoint: spontaneous echocontrast score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Willingness to switch to a biosimilar
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived efficacy of biosimilars
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: knee-extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improvement in intersegment distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nasal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nasal dome height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in columella height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to CPAP therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in OSAS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth sleepiness score (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Corneal densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Hemostatic Disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of HDP (free hemoglobin, lactic dehydrogenase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total curative rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Total success rate of stent implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total rate of extubation difficulty
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal morbidity and mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of meconium aspiration syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of combined tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of combined tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knowledge about treatment complications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Involvement in decision making (OPTION scale score)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: remission of depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of participants showing clinically significant improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: progression to clinical depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progress toward self-determined goals
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area under the curve (AUC0-12h) of desmopressin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates from male patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in faecal ammonia concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-free survival at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Patient enablement scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eligibility of patients for trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of cardiovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Physician time required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for supplemental O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of ASD
Endpoint domain: Mortality/survival
Primary endpoint: FVC % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: alert task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concurrent task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatinine change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum levels of inflammatory factors (IL‐2, IL‐6, IL‐10, TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression to surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidences of nausea, vomiting, pruritus and leg numbness
Endpoint domain: Adverse events/effects
Primary endpoint: supportive behavior scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knowledge of resources
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes against IPV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy to prevent IPV
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted lifeyears (QALYs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Markedly effective rate
Endpoint domain: Mortality/survival
Primary endpoint: Total dosage of propofol for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of acid and bile reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of bile reflux time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oral fluid concentration of nicotine and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spherical equivalents within ±1.00 and ±0.50 diopters of emmetropia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mesopic contrast sensitivity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in root mean square values for spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep-dependent performance improvement in the motor sequence task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sedation/dizziness
Endpoint domain: Adverse events/effects
Primary endpoint: Need for rescue medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CO2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of transfusions received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days on sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fibrosis progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean change in Ishak fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Wound healing improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bioavailability of manidipine and M‐XIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of delapril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure and heart rate profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VEINES-QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HVVSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RVCSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GAF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: INR return to therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of preoperative hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: flow-mediated endothelium-dependent vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Presence of SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain/comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: stair ascent time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident or worsening nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Doubling of the serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Initiation of renal-replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: prevalence of nasopharyngeal carriage of azithromycin‐resistant S. pneumoniae strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Surrogates' confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of healthcare opportunities fulfilled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Laboratory and pharmacy resource usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade 4 and 5 hematologic and skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Frankel grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean improvement in ASIA motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean number of arrested surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Dakkak dysphagia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-fundoplication symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of manual removal of the placenta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of Type 2 Diabetes Mellitus (T2DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CSP duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEP amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of late endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean CBCL total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of endometriotic lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal damage by tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pain at perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in liver triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of insulin action (tR(last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resistance to tamoxifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean amplitude of the adductor longus CMAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of oral and respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in weight and BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel loss (in μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative PWV measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of laboratory evidence of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevention of febrile illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in peak viral titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of passage through the cervical canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of participants correctly delivering a shock with AED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval from collapse to shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS-DEP score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum BDNF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dorsal stretch of metacarpophalangeal joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle force of common extensor of fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean reduction in nightmares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean global improvement (CGI-C)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General Well Being Questionnaire (WBQ) results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HBeAg seroconversion rates at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral breakthrough rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesia requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal toxicity (grades 3, 4, and 5)
Endpoint domain: Adverse events/effects
Primary endpoint: Rebleeding requiring blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month survival with Vineland Adaptive Behavior Scales ≥ 70
Endpoint domain: Mortality/survival
Primary endpoint: Detection of asymptomatic atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical complete response (CR) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone maturation (deltaBA/deltaCA ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD and BMAD normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial peak serum concentration of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacy costs
Endpoint domain: Resource use
Primary endpoint: Nurse tasking time
Endpoint domain: Resource use
Primary endpoint: Time in Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe hematological toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of overall diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of high-grade diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 30-day point-prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased CPK levels
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response over 6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S/D ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to aerobic activity prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrically evoked pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3a and neopterin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF‐alpha and IL‐8 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total body fat decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cholesterol decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: triglycerides decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-subject coefficient of variability for Cmax and AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c <7% or ≤6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic blood pressure <130 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low-density lipoprotein <2.59 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial stimulation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular stimulation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pacing lead impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes